{"type":"trials","record":{"id":41588,"source_id":"clinicaltrials-gov","external_id":"NCT05811351","title":"A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","brief_summary":"The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.","overall_status":"Completed","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Janssen Research & Development, LLC","enrollment":305,"countries":["United States","Australia","Belgium","Canada","Czechia","Denmark","Germany","Hungary","Italy","Netherlands","Poland","Portugal","Spain","Sweden","Switzerland","Turkey (Türkiye)","United Kingdom"],"start_date":"2023-03-06","completion_date":"2026-02-23","last_update_date":"2026-03-13","source_url":"https://clinicaltrials.gov/study/NCT05811351","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"60 Years","comparator":null,"organization":"Janssen Research & Development, LLC","interventions":["JNJ-81201887","Prednisone","Placebo","Triamcinolone","Sham Procedure"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Global: Change From Baseline in Square Root of Geographic Atrophy (GA) Lesion Area in the Study Eye at Month 18 — Basel…","United States (U.S.) Specific: Rate of Change in Untransformed GA Lesion Area in the Study Eye — Baseline to Month 18","Change From Baseline in Low Luminance Visual Acuity (LLVA) at Month 18 — Baseline and Month 18","Change From Baseline in Reading Speed at Month 18 — Baseline and Month 18","Change From Baseline in Retinal Sensitivity by Mesopic Microperimetry (MAIA) at Month 18 — Baseline and Month 18","Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 18 — Baseline and Month 18","Change From Baseline in Functional Reading Independence (FRI) Index at Month 18 — Baseline and Month 18","Change From Baseline in National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) Composite Score at Mont…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","source_has_results":false},"controlled_terms":["Geographic Atrophy","JNJ-81201887","Prednisone","Placebo","Triamcinolone","Sham Procedure"],"relevance_confidence":80,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05811351","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-03-06 to 2026-02-23","comparator":null,"confidence":"structured-source","population":"ALL · 60 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.838Z","intervention":["JNJ-81201887","Prednisone","Placebo","Triamcinolone","Sham Procedure"],"participants":305,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Global: Change From Baseline in Square Root of Geographic Atrophy (GA) Lesion Area in the Study Eye at Month 18 — Basel…","United States (U.S.) Specific: Rate of Change in Untransformed GA Lesion Area in the Study Eye — Baseline to Month 18","Change From Baseline in Low Luminance Visual Acuity (LLVA) at Month 18 — Baseline and Month 18","Change From Baseline in Reading Speed at Month 18 — Baseline and Month 18","Change From Baseline in Retinal Sensitivity by Mesopic Microperimetry (MAIA) at Month 18 — Baseline and Month 18","Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 18 — Baseline and Month 18","Change From Baseline in Functional Reading Independence (FRI) Index at Month 18 — Baseline and Month 18","Change From Baseline in National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) Composite Score at Mont…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","title context","study type"],"relevance_score":80,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41588","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}